Welcome to our dedicated page for Celularity news (Ticker: CELU), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Celularity Inc. (NASDAQ: CELU), headquartered in Florham Park, N.J., is a trailblazer in the field of cellular medicine. As a clinical-stage biotechnology company, Celularity is at the forefront of developing off-the-shelf, placental-derived allogeneic cell therapies. Its innovative products include unmodified natural killer (NK) cells, genetically-modified NK cells, T-cells engineered with a chimeric antigen receptor (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs). These therapies target a diverse range of conditions such as cancer, infectious diseases, and degenerative disorders.
Celularity is also a pioneer in the development and manufacture of advanced biomaterials derived from the postpartum placenta. The unique biology and availability of the placenta allow Celularity to create accessible, effective, and affordable therapeutic solutions that address significant global health challenges.
Recent Achievements and Current Projects:
- The company has received IND clearance from the FDA and is set to begin a Phase 1/2 study in 2024 with its placental-derived cell therapy.
- The Healthcare Common Procedure Coding System (HCPCS) Q code approval for Biovance® 3L has been granted by the Centers for Medicare and Medicaid Services (CMS). This code enhances the use of Biovance® 3L for wound care in office settings, enabling broader adoption and growth.
- Celularity has presented promising data from in vivo studies of its PT-CD16VS, a genetically modified allogeneic cell therapy, in combination with various monoclonal antibodies. This data highlights the therapy’s potential in treating HER2-positive cancers and other conditions.
Financial Condition and Partnerships:
The company’s financial health is under scrutiny as it works to regain compliance with Nasdaq listing requirements. Celularity is actively developing a plan to submit to Nasdaq by June 17, 2024, to address its delinquent reports. Meanwhile, the company anticipates continued growth through its advanced cell therapies and biomaterials.
Celularity’s partnerships, particularly in the field of regenerative medicine, exemplify its commitment to innovation and excellence. The company’s state-of-the-art manufacturing facility further supports its ability to produce advanced cell therapies at scale, aiming to meet the unmet needs of patients worldwide.
For more detailed information and the latest updates, visit the official website www.celularity.com.
News
Rhea-AI Summary
Celularity Inc. (NASDAQ: CELU) announces Dr. Robert Hariri's presentation on cellular therapy's potential to treat chronic conditions and extend lives at the ABUNDANCE Summit. The focus is on using placental-derived cell therapies to combat aging-related issues like immunosenescence and degenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
-
Rhea-AI Summary
Celularity Inc. (CELU) Founder and CEO, Dr. Robert Hariri, will present a keynote lecture at the Society for Brain Mapping and Therapeutics Annual World Congress discussing the potential of cellular immunotherapy in treating chronic conditions like cancer, multiple sclerosis, and Parkinson's disease. The keynote will focus on Celularity's mission to develop transformative therapies using placental-derived cells and biomaterial products. Dr. Hariri will address the broad applications of cellular immunotherapy beyond cancer, emphasizing its potential in neuroinflammatory and degenerative disorders. The company aims to lead in cellular therapeutics and collaborate with academic and industrial communities for research and investment opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.3%
Tags
-
Rhea-AI Summary
Celularity Inc. (NASDAQ: CELU) presented in vivo data on PT-CD16, a genetically modified cell therapy, at the AACR Annual Meeting 2024. The data showcased strong anti-tumor activity against gastric cancer. The company aims to combine cell therapies with approved antibodies for treating various cancers and conditions. The study revealed significant tumor volume reduction when PT-CD16VS was combined with trastuzumab compared to standard treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.67%
Tags
Rhea-AI Summary
Celularity, Inc. (CELU) announces a 1-for-10 reverse stock split of its Class A common stock to meet Nasdaq listing requirements. The split aims to increase per share price and trading appeal for institutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.48%
Tags
-
Rhea-AI Summary
Celularity Inc. (Nasdaq: CELU) announces the acceptance of its abstract for a poster presentation at the 12th World Biomaterials Congress, focusing on the potential uses of Celularity biomaterials in regenerative medicine applications. The study investigates the use of tri-layer decellularized, dehydrated human amniotic membrane technology as a carrier for induced pluripotent stem cell derived-limbal stem cells for the treatment of limbal stem cell deficiency (LSCD). This research highlights Celularity's commitment to developing advanced biomaterial products and allogeneic cell therapies to address ocular surface disorders and degenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
-
Rhea-AI Summary
Celularity Inc. (CELU) expects triple-digit percentage increases in combined net sales of its advanced biomaterial product and biobanking businesses for the first quarter 2024 and the full year 2024, compared to the same periods in 2023. The company anticipates a significant growth trajectory, driven by the commercial pipeline of advanced biomaterial products and a development pipeline that includes two product candidates. For the first quarter 2024, Celularity expects combined net sales in the range of $10.25 million to $11.5 million, with net sales percentage growth for its advanced biomaterial product business projected to be in the range of 249% to 287% compared to the first quarter 2023. For the full year 2024, the company expects net sales percentage growth of its advanced biomaterial product business to be in the range of 165% to 194% compared to full year 2023. The company's Chairman and CEO, Robert J. Hariri, emphasized the significant growth in sales of advanced biomaterial products in the fourth quarter of 2023 and expressed optimism about Celularity's unique technology platform and its potential to become a cashflow positive enterprise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.42%
Tags
Rhea-AI Summary
Celularity Inc. announced the closing of two financing transactions totaling $21 million in gross proceeds, including a $6 million private placement with its largest investor, Dragasac Limited, and a $15 million amended and restated senior secured loan agreement with an existing lender, Resorts World Inc Pte Ltd. The funding will be used to strengthen the company's balance sheet and for other purposes, including repaying all outstanding amounts owed to Yorkville under a pre-paid advance agreement. The company aims to focus on growing its operating revenue and capitalizing on opportunities in the United States and Asia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16%
Tags
-
Rhea-AI Summary
Celularity Inc. (Nasdaq: CELU) has announced its net sales expectations for the fourth quarter of 2023 and the full year of 2023. The company expects significant net sales percentage growth in the range of 176.1% to 193.0% for the fourth quarter of 2023 compared to the same period in 2022. For the full year of 2023, Celularity anticipates net sales percentage growth in the range of 22.7% to 26.6% compared to the full year of 2022. The company also revealed plans to announce net sales expectations for the first quarter of 2024 and the full year of 2024, with a focus on maintaining and building sales momentum, advancing novel product candidates, and expanding opportunistically outside their core wound care and surgical applications. Celularity also closed two separate financing transactions, receiving combined total gross proceeds of $21 million. Additionally, the company is deeply engaged in a multi-year Research Collaboration Services Agreement in cell therapy with Regeneron Pharmaceuticals, Inc., focusing on research and development of allogeneic cell therapy candidates designed to target aging processes and degenerative disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
53.72%
Tags
-
Rhea-AI Summary
Celularity Inc. (Nasdaq: CELU) has entered into an exclusive U.S. strategic commercialization agreement with BioCellgraft, Inc. for the manufacture and distribution of advanced biomaterial products for therapeutic use in oral healthcare applications. The agreement aims to tap into the large and growing markets of periodontology, implant dentistry, and oral surgery in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.25%
Tags
Rhea-AI Summary
Celularity Inc. (CELU) expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million for the fourth quarter 2023 and $22.06 million to $22.76 million for the full year 2023. The expected growth reflects triple-digit increases compared to the previous year. The company also announced a multi-year research collaboration services agreement with Regeneron.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
FAQ
What is the current stock price of Celularity (CELU)?
The current stock price of Celularity (CELU) is $2.85 as of November 21, 2024.
What is the market cap of Celularity (CELU)?
The market cap of Celularity (CELU) is approximately 61.3M.
What does Celularity Inc. specialize in?
Celularity Inc. specializes in developing off-the-shelf placental-derived allogeneic cell therapies and innovative biomaterials, targeting cancer, infectious, and degenerative diseases.
What recent achievements has Celularity accomplished?
Celularity received IND clearance from the FDA to begin a Phase 1/2 study in 2024 and secured HCPCS Q code approval for Biovance® 3L for wound care.
What are some of the key products developed by Celularity?
Key products include unmodified and genetically-modified NK cells, CAR T-cells, and mesenchymal-like adherent stromal cells (ASCs).
Where is Celularity Inc. headquartered?
Celularity Inc. is headquartered in Florham Park, New Jersey.
What are the target indications for Celularity’s therapies?
Celularity’s therapies target a range of conditions, including cancer, immunologic, infectious, and degenerative diseases.
What makes Celularity’s approach unique?
Celularity harnesses the unique biology of the placenta to create effective, accessible, and affordable therapies, focusing on unmet global needs.
What financial challenges is Celularity currently facing?
Celularity is working to regain compliance with Nasdaq listing requirements and is required to submit a compliance plan by June 17, 2024.
How does Celularity plan to scale its manufacturing?
Celularity utilizes its state-of-the-art manufacturing facility to produce advanced cell therapies at scale, ensuring consistency and meeting patient needs.
How can investors get in touch with Celularity?
Investors can contact Carlos Ramirez, Senior Vice President, Celularity Inc., via email at carlos.ramirez@celularity.com.
Where can I find more information about Celularity?
More information can be found on Celularity’s official website: www.celularity.com.
Celularity Inc.
Nasdaq:CELU
CELU Rankings
CELU Stock Data
61.34M
10.19M
53.41%
14.86%
3.38%
Biotechnology
Pharmaceutical Preparations
United States of America
FLORHAM PARK